

Bioactivity-guided isolation and identification of anti-adipogenic compounds in Shiya tea (leaves of *Adinandra nitida*)

Chunmao Yuan, Linhua Huang, Joon Hyuk Suh, and Yu Wang

J. Agric. Food Chem., **Just Accepted Manuscript** • DOI: 10.1021/acs.jafc.9b01326 • Publication Date (Web): 29 May 2019

Downloaded from <http://pubs.acs.org> on May 30, 2019

Just Accepted

“Just Accepted” manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides “Just Accepted” as a service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. “Just Accepted” manuscripts appear in full in PDF format accompanied by an HTML abstract. “Just Accepted” manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are citable by the Digital Object Identifier (DOI®). “Just Accepted” is an optional service offered to authors. Therefore, the “Just Accepted” Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the “Just Accepted” Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these “Just Accepted” manuscripts.

1 **Bioactivity-guided isolation and identification of anti-adipogenic**
2 **compounds in Shiya tea (leaves of *Adinandra nitida*)**

3
4 Chunmao Yuan,^{†, ‡, ⊥} Linhua Huang,^{†, ||, ⊥} Joon Hyuk Suh,[†] Yu Wang,^{†, *}

5
6 [†] Citrus Research and Education Center, Food Science and Human Nutrition, University of
7 Florida, 700 Experiment Station Road, Lake Alfred, Florida 33850, United States

8 [‡] State Key Laboratory of Functions and Applications of Medicinal Plants, Guizhou Medical
9 University, 3491 Baijin Road, Guiyang 550014, People's Republic of China

10 ^{||} Citrus Research Institute, Southwest University, Xiema, Beibei, Chongqing 400712, People's
11 Republic of China

12
13
14
15 *Corresponding Author:

16 Yu Wang, Ph.D.

17 Department of Food Science and Human Nutrition

18 Citrus Research and Education Center

19 University of Florida

20 700 Experiment Station Rd, Lake Alfred, FL 33850 USA

21 Tel: +1-863-956-8673

 E-mail: yu.wang@ufl.edu

Abstract

Obesity is a worldwide epidemic contributing to a higher risk of developing maladies such as type 2 diabetes, heart disease, and cancer. Shiya tea (leaves of *Adinandra nitida*), a traditional Chinese tea, is widely consumed due to its palatable flavor and various curative effects, such as reducing blood pressure and blood lipids, as well as anti-inflammation, etc. However, no relevant research on the anti-obesity effects of Shiya tea has been reported. In particular, no health benefiting compounds, other than flavonoids, in Shiya tea have been reported. Thus, 3T3-L1 preadipocytes have been used as a bioactivity-guided identification model to verify the inhibitory effects of Shiya tea on adipogenesis, as well as identify anti-adipogenic compounds. Four triterpenoid saponins (**1–4**), including one new compound (**2a**, **3 α -dihydroxy-ursolic acid-28-O- β -D-glucopyranosyl ester**, compound **1**), and a flavonoid (**5**) have been identified using NMR (1D and 2D NMR) and LC–MS techniques. Compound **1**, the major anti-adipogenic constituent with an IC₅₀ value of 27.6 μ g/mL, has been identified for the first time in Shiya tea. In order to understand the structure-activity relationship, three hydrolytic compounds (**1s**, **2s**, and **5s**) were obtained to provide an inhibitory effect on lipid accumulation during 3T3-L1 adipocyte differentiation. The inhibitory effect of the triterpenoid (**1s**) possessing no sugar group decreased significantly, while the flavonoid (**5s**) also without a sugar group showed increased activity. In addition, the hydroxyl group position may also play a role in inhibitory efficacy.

42

43

KEYWORDS: Shiya tea, anti-adipogenesis, bioactivity-guided isolation, triterpenoid saponins, structure-activity relationship

45

46 INTRODUCTION

47 Obesity is a worldwide epidemic contributing to a higher risk of developing maladies
48 such as type 2 diabetes, heart disease, and cancer.¹⁻³ According to the World Health
49 Organization (WHO), nearly two billion adults worldwide are overweight and over
50 500,000,000 are obese.⁴ Previously, only five drugs have been approved by the FDA to treat
51 obesity, but reports indicate various side effects from their usage.⁵ Therefore, searching for
52 alternative therapies or using natural resources to prevent obesity with little or no side effects
53 has become a necessity.

54 *Adinandra nitida* (Theaceae), a shrub or tree, is mainly distributed in the southern part of
55 China, such as Guangdong, Guangxi, Guizhou and Yunnan Provinces.⁶ The leaves of *A. nitida*,
56 have long been consumed as a traditional tea (Shiya tea) beverage in China,^{6, 7} due to its
57 palatable flavor and many curative effects, such as reducing blood pressure and blood lipids,
58 as well as anti-inflammation, etc.^{8,9} Previous studies indicated that Shiya tea is rich in
59 flavonoids, such as camellianin A, camellianin B, and apigenin, with great radical scavenging
60 ability for 1,1-diphenyl-2-picrylhydrazyl (DPPH) and antitumor activities.^{7,8} Flavonoids in
61 Shiya tea are considered the major active and functional chemical constituents.¹⁰⁻¹³ However,
62 there has been no studies indicating additional compounds, other than flavonoids, in Shiya tea
63 demonstrate any bioactivities, in particular anti-obesity effects. In order to explore other
64 potential bioactive compounds in Shiya tea, as well as potential to prevent obesity, its inhibitory
65 effects of adipogenesis using 3T3-L1 preadipocytes has been conducted, and the bioactivity-
66 guided identification of anti-adipogenic compounds has also been performed. Consequently,
67 bioactivity-guided isolation of the methanol extract led to the isolation and identification of
68 four triterpenoid saponins (**1–4**), including one new compound (**1**), and a flavonoid (**5**) using

69 NMR (1D and 2D NMR) and LC-MS techniques. The new triterpenoid saponin (**1**), the major
70 active constituent in Shiya tea, reduced intracellular lipid accumulation in 3T3-L1 adipocytes.
71 The structure-activity relationship of triterpenoid saponins is also discussed.

72

73 **MATERIALS AND METHODS**

74 **Materials.** Analytical (250 μm thickness, 2–25 μm particle size) TLC plates were purchased
75 from Macherey-Nagel company (Macherey-Nagel, Germany). Silica gels for column
76 chromatography (100–200 or 200–300 mesh, (Thermo Scientific, CA, USA) and Sephadex
77 LH-20 (Thermo Scientific, CA, USA) were obtained from Thermo Scientific. Methoxyamine,
78 N-methyl-N-(trimethylsilyl)trifluoroacetamide, and pyridine were used for preparing derivative
79 of the glucose (Sigma-Aldrich, USA). LC-MS grade acetonitrile, water, and formic acid and
80 ACS-grade n-hexane, ethyl acetate, acetone, chloroform and methanol were purchased from
81 Sigma-Aldrich. Shiya tea samples were produced in Zhaoping of Guangxi Province, China in
82 May 2018.

83 **LC-MS Analysis.** LC-MS analysis was conducted using a Vanquish UHPLC system
84 (UHPLC+ focused pump, autosampler, and column compartment) coupled with a Q Exactive
85 mass spectrometer (Thermo Fisher Scientific, San Jose, CA, USA) via an electrospray
86 ionization (ESI) interface. Chromatographic separation for crude extract and isolates were
87 performed using an ACQUITY UPLC BEH C18 column (150 mm \times 2.1 mm id, 5 μm , Waters,
88 Milford, MA, USA). The mobile phase consisted of 0.1% formic acid in water (solvent A) and
89 0.1% formic acid in acetonitrile (solvent B). The sample was eluted with the following linear
90 gradient: 25–65% B from 0–12 min, 65–98% B from 12–15 min, and maintain at 98% from
91 15–22 min. The flow rate was 0.2 mL/min, and the injection volume was set at 2 μL . The

92 column temperature was maintained at 40 °C. The MS parameters were as follows: negative
93 ionization mode, capillary temperature of 250 °C, sheath gas (N₂) flow rate of 45 psi, aux gas
94 (N₂) flow rate of 10 psi, ion spray voltage of 2.5 kV, and S-lens RF level of 50. Full MS scans
95 in the FT cell were acquired in the range of *m/z* 65–975 with a mass resolution of 70,000, AGC
96 target of 1,000,000 and maximum IT of 246 ms. The MS/MS experiments were set as data
97 dependent scan (dd-MS²) with a mass resolution of 17,500, AGC target of 200,000 and
98 maximum IT of 54 ms. The isolation window was set at *m/z* 1.0, and the stepped collision
99 energy was used at 20, 40 and 60 eV. Xcalibur (Ver. 4.0) was employed for data collection and
100 analysis.

101 **NMR Analysis.** ¹H (600 or 400 MHz), ¹³C (150 or 100 MHz), ¹H–¹H COSY (correlation
102 spectroscopy), ¹H–¹³C HMQC (heteronuclear multiple quantum correlation), ¹H–¹H ROESY
103 (rotating frame overhauser effect spectroscopy), and HMBC (heteronuclear multiple bond
104 correlation) NMR spectra were acquired on a Bruker 600 MHz instrument. Compounds **1–4**,
105 **1s**, and **2s** were analyzed in CD₃OD, while compounds **5** and **5s** were measured in pyridine-*d*₅.

106 **Purification of Compounds 1–5.** Shiya tea (4.0 kg) was powdered and soaked in MeOH (20
107 L) three times at 25 °C. The combined extract was filtered and concentrated with a rotary
108 evaporator to yield crude extract (0.7 kg), which was suspended in water and then extracted
109 with EtOAc (3 × 5 L) resulting in the corresponding extracts: EtOAc (200 g) and water layer
110 (500 g). The anti-adipogenic effects were evaluated by measuring inhibition of adipogenic
111 differentiation in 3T3-L1 preadipocytes. The active EtOAc fraction was applied to a silica gel
112 CC (7.62 cm × 65 cm id) and eluted with petroleum ether/acetone (50:1, 20:1, 10:1, 5:1, 2:1,
113 1:1, and 0:1 v/v, each 25 L) to create four fractions (Fr. 1–Fr.4), in which only Fr. 3 showed
114 better anti-adipogenic activity. Then, Fr. 3 (40 g) was subjected to an ODS CC (6.35 cm × 48

115 cm id, MeOH/H₂O, 40, 50, 60, 70, 80, and 100% v/v, each 300 mL) resulting in five fractions
116 (Fr. 3A–Fr.3E), in which only Fr.3D was active. Next, Fr.3D (20 g) was fractionated using a
117 gradient of CH₂Cl₂/MeOH (50:1, 30:1, 10:1 v/v, each 3 L) to obtain subfractions. Fr. 3D.1–
118 Fr.3D.5. Fr.3D.1 (7 g) was further purified on a silica gel CC using CH₂Cl₂/acetone (3:2, 1:1
119 v/v, each 10 L) to furnish **1** (2.0 g) and **2** (1.0 g). Fr.3D.2 (4 g) was subjected to a Sephadex
120 LH-20 CC (145 cm × 4.5 cm id) flushed with MeOH giving rise to five subfractions (Fr.
121 3D.2.1–Fr. 3D.2.5), and Fr.3D.2.3 was then purified by a semi-preparative HPLC (52%
122 MeOH/H₂O for 50 min, v/v, 4 mL/min) with an X-bridge column (250 mm × 20 mm, 5 μm) to
123 afford **3** (200 mg) and **4** (210 mg) with retention times of 37.0 and 44.5 min, respectively.
124 Fr.3D.5 (5 g) was repeatedly recrystallized in EtOAc to afford **5** (3.0 g).

125 **2a, 3a-Dihydroxy-ursolic acid-28-O-β-D-glucopyranosyl ester (1)**. White, amorphous
126 powder; $[\alpha]_D^{25} +27$ (c 0.4, MeOH); IR ν_{\max} 3397, 2939, 2864, 1753, 1458, 1379, 1067, 1027,
127 605, 583 cm⁻¹; ¹H and ¹³C NMR data, see Table 1; HR-ESI-MS: *m/z* calcd. for C₃₇H₅₉O₁₁ [M
128 + HCOO]⁻ 679.4057 found 679.4064.

129 **Kajiichigoside F1 (2)**. White amorphous powder; HR-ESI-MS: *m/z* calcd. for C₃₇H₅₉O₁₂ [M +
130 HCOO]⁻ 695.4007 found 695.4014. ¹H NMR (400 HMz, CD₃OD): δ_H 0.79 (s, 3H), 0.89 (s,
131 3H), 0.95 (d, 3H, *J* = 5.2 Hz, H-30), 1.01 (s, 3H), 1.01 (s, 3H), 1.23 (s, 3H), 1.37 (s, 3H), 3.70,
132 (dd, 1H, *J* = 11.8, 4.2 Hz, H-6a), 3.82, (dd, 1H, *J* = 11.8, 4.2 Hz, H-6b), 3.95, (dt, 1H, *J* = 11.8,
133 3.5 Hz, H-2), 5.33 (t, 1H, *J* = 2.9 Hz, H-12), 5.34 (d, 1H, *J* = 8.6 Hz, H-1'); ¹³C NMR (100
134 HMz, CD₃OD): δ_C 15.2 (CH₃, C-30), 15.6 (CH₃, C-25), 16.3 (CH₃, C-26), 17.9 (CH₂, C-6),
135 21.1 (CH₃, C-24), 23.4 (CH₂, C-11), 25.1 (CH₃, C-27), 25.7 (CH₂, C-16), 25.8 (CH₂, C-21),
136 27.9 (CH₃, C-29), 28.3 (CH₂, C-15), 29.3 (CH₃, C-23), 32.6 (CH₂, C-7), 36.9 (CH₂, C-22), 38.0
137 (C, C-10), 38.1 (C, C-4), 40.0 (C, C-8), 41.2 (C, C-14), 41.4 (CH, C-20), 41.6 (CH₂, C-1), 46.8

138 (CH, C-9), 47.9 (C, C-17), 48.1 (CH, C-5), 53.6 (CH, C-18), 61.0 (CH, C-6'), 65.8 (CH, C-2),
139 69.7 (CH, C-4'), 72.5 (CH, C-2'), 72.3 (CH, C-19), 76.9 (CH, C-5'), 77.2 (CH, C-3'), 78.7 (CH,
140 C-3), 94.4 (CH, C-1'), 128.2 (CH, C-12), 138.3 (C, C-13), 177.1(C, C-28)

141 **Glucosyl tormentate (3)**. White amorphous powder; HR-ESI-MS: m/z calcd. for $C_{37}H_{59}O_{12}$
142 $[M + HCOO]^-$ 695.4007 found 695.4014; 1H NMR (400 HMz, CD_3OD): δ_H 0.80 (3H, s), 0.83
143 (3H, s), 0.95 (3H, d, $J = 6.0$ Hz), 1.03 (3H, s), 1.22 (3H, s), 1.35 (3H, s), 5.33 (1H, s, H-12),
144 5.34 (1H, d, $J = 8.5$, H-1 of glucose); ^{13}C NMR (100 HMz, CD_3OD): δ_C 15.2 (CH₃, C-30), 15.7
145 (CH₃, C-26), 16.0 (CH₃, C-25), 16.2 (CH₃, C-24), 18.3 (CH₂, C-6), 23.3 (CH₂, C-11), 23.4
146 (CH₃, C-27), 25.1 (CH₂, C-16), 25.7 (CH₂, C-21), 25.8 (CH₃, C-29), 27.9 (CH₂, C-15), 28.2
147 (CH₃, C-23), 32.7 (CH₂, C-7), 36.9 (CH₂, C-22), 37.8 (C, C-10), 39.1 (C, C-8), 39.9 (C, C-4),
148 41.3 (CH, C-20), 41.6 (C, C-14), 46.8 (CH, C-9), 48.0 (CH₂, C-1), 48.2 (C, C-17), 53.6 (CH,
149 C-18), 55.3 (CH, C-5), 61.1 (CH, C-6'), 68.1 (CH₂, C-2), 69.7 (CH, C-4'), 72.2 (C, C-19), 72.5
150 (CH, C-2'), 76.9 (CH, C-5'), 77.2 (CH, C-3'), 83.2 (CH, C-3), 94.4 (CH, C-1'), 138.4 (CH, C-
151 12), 128.1 (C, C-13), 177.1 (C, C-28).

152 **2 α ,3 α ,19 α -Trihydroxy-olean-12-en-28-oic acid-28-O- β -D-glucopyranoside (4)**. White
153 amorphous powder; HR-ESI-MS: m/z calcd. for $C_{37}H_{59}O_{12}$ $[M + HCOO]^-$ 695.4007 found
154 695.4019. 1H NMR (400 HMz, CD_3OD): δ_H 0.77 (s, 3H, H-24), 0.83 (s, 3H, H-30), 0.96 (d,
155 3H, H-25), 0.97 (d, 3H, H-29), 1.02 (s, 3H, H-26), 1.03 (s, 3H, H-23), 1.31 (s, 3H, H-27), 3.70,
156 (dd, 1H, $J = 11.8, 4.2$ Hz, H-6a), 3.84, (dd, 1H, $J = 11.8, 4.2$ Hz, H-6b), 3.95, (dt, 1H, $J = 11.8,$
157 3.5 Hz, H-2), 5.35 (t, 1H, $J = 2.9$ Hz, H-12), 5.40 (d, 1H, $J = 8.6$ Hz, H-1'); ^{13}C NMR (400
158 HMz, CD_3OD): δ_C 15.6 (CH₃, C-25), 16.0 (CH₃, C-26), 16.4 (CH₂, C-6), 18.3 (CH₃, C-24),
159 23.5 (CH₂, C-11), 23.6 (CH₃, C-30), 23.8 (CH₃, C-27), 27.2 (CH₂, C-16), 27.9 (CH₃, C-29),
160 28.0 (CH₂, C-21), 28.0 (CH₂, C-15), 31.9 (CH₃, C-23), 32.4 (CH₂, C-7), 34.6 (CH₂, C-22), 38.0

161 (C, C-20), 38.2 (C, C-9), 39.1 (C, C-10), 39.1 (C, C-4), 39.5 (C, C-8), 41.3 (C, C-14), 43.7
162 (CH₂, C-1), 45.7 (CH, C-18), 46.7 (C, C-17), 48.4 (CH, C-5), 61.0 (CH, C-6'), 68.1 (CH, C-2),
163 69.7 (CH, C-4'), 72.5 (CH, C-2'), 77.0 (CH, C-5'), 77.3 (CH, C-3'), 81.0 (CH, C-3), 83.2 (CH,
164 C-19), 94.4 (CH, C-1'), 123.4 (CH, C-12), 142.6 (C, C-13), 177.2 (C, C-28).

165 **Camellianin A (5)**. White amorphous powder; HR-ESI-MS: *m/z* calcd. for C₂₉H₃₁O₁₅ [M – H][–]
166 619.1663 found 619.6154; ¹H NMR (400 HMz, pyridine-*d*₅): δ_H 1.66 (3H, d, *J* = 6.0 Hz, H-
167 6''), 1.90 (3H, s, H-8''), 6.41 (1H, s, H-6), 6.73 (1H, s, H-3), 6.97 (1H, s, H-8), 7.18 (2H, d, *J* =
168 8.6 Hz, H-3' and H-5'), 7.80 (2H, d, *J* = 8.6 Hz, H-2' and H-6'); ¹³C NMR (100 HMz, CD₃OD):
169 δ_C 20.1 (CH₃, C-6''), 21.8 (CH₃, C-8''), 65.1 (CH₂, C-6''), 71.4 (CH, C-5''), 72.8 (CH, C-2''),
170 73.8 (CH, C-4''), 73.9 (CH, C-3''), 75.9 (CH, C-2''), 76.3 (CH, C-5''), 78.7 (CH, C-3''), 80.3
171 (CH, C-4''), 98.8 (C, C-8), 100.6 (CH, C-1''), 102.2 (CH, C-6), 102.6 (CH, C-1''), 108.2 (CH,
172 C-3), 109.8 (C, C-10), 118.0 (CH, C-3' and C-5'), 123.7 (C, C-1'), 129.8 (CH, C-2' and C-6'),
173 159.9 (C, C-5), 161.3 (C, C-9), 162.8 (C, C-7), 164.0 (C, C-4'), 165.5 (C, C-2), 172.0 (C, C-
174 7''), 178.5 (C, C-4).

175 **Verification of D-glucose isomer for compound 1**. Compound **1** (2 mg) was heated with 2 M
176 HCl (water, 2 mL) at 80 °C for 2 h. After cooling, the reaction mixture was extracted with
177 CHCl₃ (3 × 2 mL). The aqueous layer was then evaporated to dryness using MeOH until
178 neutral.¹⁴ The dried residue was mixed with 90 μL of methoxyamine hydrochloride (20 mg/mL
179 in pyridine) and vortexed for 2 h at room temperature. Afterward, 240 μL of N-methyl-N-
180 (trimethylsilyl)trifluoroacetamide were added to the sample, and the mixture was vortexed for an
181 additional 30 min.¹⁵

182 GC-MS analysis of the derivatized sample was conducted using a Clarus 680 GC (Perkin-
183 Elmer, Inc., Waltham, MA) equipped with a Clarus SQ 8T MS in EI mode with 70 eV. The

184 sample solution (1 μL) was injected into an Rxi-5 MS capillary column (30 m \times 0.25 mm, 0.25
185 μm film thickness). The oven temperature was programmed at 70 $^{\circ}\text{C}$ for 5 min, rised to 270 $^{\circ}\text{C}$
186 at a rate of 4 $^{\circ}\text{C}/\text{min}$, and then increased to 320 $^{\circ}\text{C}$ (5 min hold) at a rate of 20 $^{\circ}\text{C}/\text{min}$. The
187 flow rate of the carrier gas, helium, was 1.1 mL/min. The configuration of D-glucose for
188 compound **1** was established by comparing the retention time and molecular weight of the
189 corresponding derivative to that of the standard, D-glucose.¹⁵

190 **Hydrolysis of compounds 1, 2 and 5 for structure-activity study.** A solution of **1** (30 mg)
191 or **2** (30 mg) in 5 mL MeOH was added to 1 M HCl (5 mL) and stirred at 70 $^{\circ}\text{C}$ for 2 h. The
192 mixture solution was next added to 10 mL water and then extracted with ethyl acetate (3 \times 30
193 mL). The organic layer was concentrated using a rotary evaporator and then purified using
194 flash chromatography with a gradient of $\text{CH}_2\text{Cl}_2/\text{acetone}$ (9:1, 8:2, 6:4 v/v, each 50 mL) to
195 obtain the pure compounds **1s** (20 mg) or **2s** (21 mg).¹⁴

196 2 M HCl (water, 3 mL) and compound **5** (30 mg) in MeOH (3 mL) were heated at 80 $^{\circ}\text{C}$
197 for 2 h. After cooling, the reaction mixture was extracted with ethyl acetate (3 \times 10 mL). The
198 organic layer was concentrated using a rotary evaporator, which then was purified using flash
199 chromatography with a gradient of $\text{CH}_2\text{Cl}_2/\text{acetone}$ (8:2, 6:4:1 v/v, each 50 mL) to yield **5s** (18
200 mg). The spectroscopic data of compounds **1s**, **2s**, and **5s** are listed below. The compounds **1**,
201 **2**, and **5** and their hydrolyzed compounds were applied to 3T3-L1 cell cultures to understand
202 the structure-activity relationship.

203 **2 α , 3 α -Dihydroxy-ursolic acid (1s).** White amorphous powder; HR-ESI-MS: m/z calcd. for
204 $\text{C}_{30}\text{H}_{47}\text{O}_4$ [$\text{M} - \text{H}$]⁻ 471.3474 found 471.3484; ¹H NMR (400 HMz, CD_3OD): δ_{H} 0.86 (s, 3H,
205 H-26), 0.89 (s, 3H, H-24), 0.91 (br s, 3H, H-29), 1.00 (d, 3H, $J = 6.8$ Hz, H-30), 1.01 (s, 3H,
206 H-23), 1.03 (s, 3H, H-25), 1.16 (s, 3H, H-27), 2.23 (d, 1H, $J = 11.0$ Hz, H-18), 3.34 (m, 1H,

207 H-3), 3.95 (dt, 1H, $J = 11.8, 3.5$ Hz, H-2), 5.26 (t, 1H, $J = 3.6$ Hz, H-12); ^{13}C NMR (100 HMz,
208 CD_3OD): δ_{C} 15.6 (CH_3 , C-25), 16.3 (CH_3 , C-29), 16.4 (CH_3 , C-26), 17.7 (CH_2 , C-6), 20.2
209 (CH_3 , C-30), 21.1 (CH_3 , C-24), 22.8 (CH_3 , C-27), 23.0 (CH_2 , C-11), 23.9 (CH_2 , C-16), 27.8
210 (CH_3 , C-23), 27.9 (CH_2 , C-15), 30.4 (CH_2 , C-21), 32.8 (CH_2 , C-7), 36.7 (CH_2 , C-22), 38.0 (C,
211 C-10), 38.1 (C, C-4), 39.0 (CH, C-20), 39.0 (CH, C-19), 39.6 (C, C-8), 41.2 (CH_2 , C-1), 42.0
212 (C, C-14), 47.2 (CH, C-9), 47.9 (CH, C-5), 48.2 (C, C-17), 52.9 (CH, C-18), 65.7 (CH, C-2),
213 78.7 (CH, C-3), 125.4 (CH, C-12), 138.3 (C, C-13), 180.2 (C, C-28).

214 **Euscaphic acid (2s)**. HR-ESI-MS: m/z calcd. for $\text{C}_{30}\text{H}_{47}\text{O}_5$ $[\text{M} - \text{H}]^-$ 487.3423 found 487.3419.

215 ^1H NMR (400 HMz, CD_3OD): δ_{H} 0.81 (s, 3H, H-24), 0.89 (s, 3H, H-25), 0.95 (d, 3H, $J = 5.2$
216 Hz, H-30), 1.01 (s, 3H, H-26), 1.01 (s, 3H, H-23), 1.22 (s, 3H, H-29), 1.37 (s, 3H, H-27), 3.35,
217 (m, 1H, H-3), 3.95, (dt, 1H, $J = 11.8, 3.5$ Hz, H-2), 5.32 (t, 1H, $J = 4.0$ Hz, H-12); ^{13}C NMR
218 (100 HMz, CD_3OD): δ_{C} 15.2 (CH_3 , C-30), 15.5 (CH_3 , C-25), 16.1 (CH_3 , C-26), 17.9 (CH_2 , C-
219 6), 21.1 (CH_3 , C-24), 23.3 (CH_2 , C-11), 23.5 (CH_3 , C-27), 25.2 (CH_2 , C-16), 25.7 (CH_2 , C-21),
220 25.9 (CH_3 , C-29), 27.9 (CH_2 , C-15), 28.2 (CH_3 , C-23), 38.0 (C, C-10), 38.1 (C, C-4), 39.9 (C,
221 C-8), 32.7 (CH_2 , C-7), 37.6 (CH_2 , C-22), 41.1 (CH, C-20), 41.3 (CH_2 , C-1), 41.7 (C, C-14),
222 46.8 (CH, C-9), 47.3 (C, C-17), 47.9 (CH, C-5), 53.7 (CH, C-18), 65.8 (CH, C-2), 72.2 (CH,
223 C-19), 78.7 (CH, C-3), 128.0 (CH, C-12), 138.7 (C, C-13), 180.9 (C, C-28).

224 **Apigenin (5s)**. White amorphous powder; HR-ESI-MS: m/z calcd. for $\text{C}_{37}\text{H}_{59}\text{O}_{12}$ $[\text{M} - \text{H}]^-$

225 269.0450 found 269.0449; ^1H NMR (400 HMz, pyridine- d_5): δ_{H} 6.75 (1H, s, H-6), 6.84 (1H, s,
226 H-3), 6.90 (1H, s, H-8), 7.23 (2H, d, $J = 8.6$ Hz, H-3' and H-5'), 7.90 (2H, d, $J = 8.6$ Hz, H-2'
227 and H-6'); ^{13}C NMR (100 HMz, CD_3OD): δ_{C} 94.7 (C, C-8), 99.8 (CH, C-6), 103.7 (CH, C-3),
228 104.8 (C, C-10), 116.6 (CH, C-3' and C-5'), 122.0 (C, C-1'), 128.7 (CH, C-2' and C-6'), 158.3
229 (C, C-5), 162.5 (C, C-9), 162.9 (C, C-7), 164.3 (C, C-4'), 165.7 (C, C-2), 182.5 (C, C-4).

230 **Cell culture and adipocyte differentiation.** 3T3-L1 cells (American Type Culture Collection;
231 ATCC CL-193, Rockville, MD, USA) were grown in Dulbecco's modified Eagle's medium
232 (DMEM) containing 10% bovine calf serum (BS), 100 units/mL penicillin, and 50 $\mu\text{g}/\text{mL}$
233 streptomycin in an incubator with 5% CO_2 at 37 $^\circ\text{C}$. For differentiation experiments, 3T3-L1
234 preadipocytes were cultured in 24-well plates until confluent, and then maintained for two
235 additional days. Afterwards, differentiation was induced with a mixture of 1 μM
236 dexamethasone (Dex), 5 $\mu\text{g}/\text{mL}$ insulin, 0.5 mM 3-isobutyl-1-methylxanthine (IBMX), and the
237 sample in DMEM containing 10% fetal bovine serum (FBS). Two days later, medium was
238 replaced with fresh DMEM supplemented with 10% FBS and 5 $\mu\text{g}/\text{mL}$ insulin for 2 days. Then,
239 the medium for the maturing adipocytes was replaced with 10% FBS in DMEM for another 2
240 days. Finally, cells were stained with Oil Red O. All samples were dissolved in dimethyl
241 sulfoxide (DMSO) before apply to preadipocytes. The final concentration of DMSO was less
242 than 0.2%.

243 **Oil Red O staining.** Differentiated 3T3-L1 adipocytes were fixed with 10% formaldehyde in
244 phosphate-buffered saline (PBS) for 30 min at room temperature, and washed twice with PBS.
245 Fixed cells were stained with Oil Red O solution (0.3% Oil Red O in 60% isopropyl alcohol)
246 for 20 min, followed by two PBS rinses. Stained lipid droplets of the 3T3-L1 adipocytes were
247 photographed using an Olympus IX73 microscope (Tokyo, Japan) at 200 \times magnification.
248 Finally, the dye retained in the cells was dissolved in isopropyl alcohol and quantified by
249 measuring the absorbance at 490 nm using a microplate reader (FlexStation 3TM, Molecular
250 Devices, Sunnyvale, CA, USA).

251 **Cytotoxicity assay.** The cytotoxic effects of samples on 3T3-L1 cells were estimated using an
252 MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay. Briefly, cells

253 were cultured in 96-well plates until the full confluence, and incubated with the presence or
254 absence of sample in differentiation medium for 4 days, and then exposed to 10% FBS in
255 DMEM for an additional day without the sample. The effective fractions and samples didn't
256 show cytotoxicity. Then, the MTT was added into each well at a final concentration of 0.5
257 mg/mL and placed in an incubator for 4 hours. After removal of medium and MTT solution,
258 the formazan was dissolved using 200 μ L DMSO and quantified by measuring the absorbance
259 at 570 nm by using a microplate reader.

260 **Statistical analysis.** All results of bioactivity testing were expressed as the mean \pm standard
261 deviation (SD) ($n = 3$). Statistical comparisons were determined by student T-test. A *P*-value
262 of < 0.05 was considered significant.

263

264 **RESULTS AND DISCUSSION**

265 **Bioassay-guided Isolation of Potential Anti-adipogenic Compounds from Shiya tea.** Each
266 fraction isolated from MeOH extracts of Shiya tea was screened for potential anti-adipogenic
267 effects (Figure 1). Only the active fractions were used for the further isolation. The ethyl acetate
268 layer was subjected to a silica gel column to obtain different fractions, and only Fr.3 was active.
269 Fractions 3B and 3B1, which were fractionated/sub-fractionated from Fr. 3, significantly
270 inhibited intracellular lipid accumulation at 100 μ g/mL during 3T3-L1 adipocyte
271 differentiation without cytotoxicity. From Fr. 3B1, five compounds were isolated.

272 **Structure Elucidation of Compounds (1–5) from Shiya tea.** Bioactivity-guided isolation of
273 MeOH extracts of Shiya tea led to the isolation of four triterpenoid saponins (1–4), including
274 one new compound (1), and a flavonoid (5) (Figure 2), which were elucidated using

275 spectroscopic methods (1D, 2D NMR, and LC–Orbitrap–MS). Four known compounds,
276 kajiichigoside F1 (**2**),¹⁷ glucosyl tormentate (**3**),¹⁸ 2 α , 3 α , 19 α -trihydroxy-olean-12-en-28-oic
277 acid-28-O-beta-D-glucopyranoside (**4**),¹⁹ and camellianin A (**5**)²⁰ were identified by comparing
278 their spectroscopic data with those reported in the literature.

279 2 α , 3 α -Dihydroxy-ursolic acid-28-O- β -D-glucopyranosyl ester (**1**), of which structure has
280 been not reported, was white amorphous powder with a molecular formula of C₃₆H₅₈O₉ based
281 on *m/z* 679.4064 [M + HCOO]⁻ (calcd. for C₃₇H₅₉O₁₁, 679.4057) with 8 degrees of unsaturation.
282 The ¹H NMR spectra (Table 1) revealed the presence of seven methyls [δ_{H} 0.85 (s), 0.88 (s),
283 0.92 (d, *J* = 6.2 Hz), 0.99 (d, *J* = 5.2 Hz), 1.00 (s), 1.03 (s), 1.15 (s)], and an olefinic proton
284 at δ_{H} 5.28 (d, *J* = 2.9 Hz). The 1D NMR data along with the HMQC spectra showed 36 carbon
285 signals, including a characteristic glucose, two hydroxyls, a double bond and a carbonyl. The
286 above-mentioned information indicated that **1** was an ursane-type triterpenoid saponin.

287 Further analysis of the 1D and 2D NMR data of **1** suggested a high similarity between **1**
288 and glucosyl tormentate (**3**) except for the relative configuration of OH-3 and absence of a
289 hydroxyl at C-19.¹⁷ In the ¹H-¹H COSY spectrum (Figure 3), two isolated spin systems were
290 observed as H₂-1/H-2/H-3 and Me-29/H-19/H-20/Me-30, which revealed the presence of two
291 fragments as indicated by the highlighted bold bonds in Figure 3. The fragments were further
292 confirmed from the HMBC correlations of Me-23 to C-3, C-4, and C-5, Me-29 to C-18, C-19,
293 and C-20, and Me-30 to C-19, C-20, and C-21 (Figure 3). The glucose was connected to the
294 carbonyl of C-28 by the key HMBC correlation from the anomeric proton of H-1' (δ_{H} 5.36, d,
295 *J* = 8.6 Hz) to C-28 (δ_{C} 176.6), and the coupling constant indicated that the glucopyranose was
296 β -oriented. D-glucose was obtained from acid hydrolysis of **1**, which was determined by GC
297 analysis of corresponding derivatives.¹⁴ Thus, the planar structure of **1** was assigned.

298 The relative configuration of **1** was assigned from the ROESY correlations and coupling
299 constant, in which cross-peaks of H-2/H-3, H-2/Me-25, H-3/Me-24, Me-25/M-26, and Me-
300 29/H-20 implied that those groups were cofacial and randomly assigned as β -oriented (Figure
301 3). The coupling constant between H-2 and H-3 ($J = 3.5$ Hz) along with the chemical shift of
302 C-2 (δ_C 65.8) and C-3 (δ_C 78.8) further confirmed the β -orientation of H-2 and H-3.^{17,19} In
303 addition, H-5, H-9, H-19, and Me-30 were α -oriented due to the ROESY correlations of H-
304 5/H-9, H-9/Me-27, and Me-30/H-19. Therefore, the relative configuration of **1** was constructed
305 as $2\alpha, 3\alpha$ -dihydroxy-ursolic acid-28-O- β -D-glucopyranosyl ester.

306 **MS Fragmentation Patterns of Authentic Isolates (1–5).** Four triterpenoid saponins had the
307 predominant $[M - H]^-$ and $[M + HCOO]^-$ precursor ions due to the presence of formic acid in
308 the mobile phase (Table 2). The cleavage of sugar moieties from the compound structures were
309 the characteristic fragmentation in all isolates (Table 2). Compounds (**1–4**) generated fragment
310 ions with the loss of glucose (m/z 162), and compound (**5**) formed a fragment ion with the loss
311 of glucose (m/z 162) and rhamnose (m/z 146). Compound **1**, the new triterpenoid saponin,
312 without the hydroxyl at C-19 had only one fragment ion $[M - Glu - H]^-$ in the MS² spectra,
313 while others were found to generate more fragments, such as the loss of a carboxylic acid at C-
314 28 and H₂O. The LC–MS chromatogram of the isolates (**1–5**) in crude extract was shown in
315 Figure 4.

316 **Potential Anti-adipogenic Effects of Purified Compounds and their hydrolyzed**
317 **compounds.** All the isolates (**1–5**) were evaluated by measuring the inhibitory effect on lipid
318 accumulation in 3T3-L1 adipocytes (Figure 5). The intracellular lipid accumulation and lipid
319 droplets were significantly suppressed by **1** in a dose-dependent manner (Figure 6) with an IC₅₀
320 value of 27.6 μ g/mL without cytotoxicity. As for the ursane- and oleanane-type triterpenoids

321 (1–4), the absence of the hydroxyl at C-19 was important for inhibitory effect on lipid
322 accumulation in 3T3-L1 adipocytes. Therefore compound **1**, without a hydroxyl at C-19
323 revealed the most effective inhibition of 3T3-L1 adipocyte differentiation. In order to discuss
324 the effect of a sugar group on the bioactivity, three aglycones of 2 α , 3 α -dihydroxy-ursolic acid
325 (**1s**),²¹ euscaphic acid (**2s**)¹⁷, and apigenin (**5s**)²² were obtained by hydrolysis of compounds **1**,
326 **2**, and **5**, respectively. When β -D-glucopyranose was removed by acid hydrolysis from
327 compound **1**, the percentage of lipid accumulation increased from 47.6 % to 85.4% at 40 μ g/mL.
328 Both aglycones of **1s** and **2s** showed no obvious anti-adipogenic activity indicating the effect
329 of the position of a hydroxyl was not conclusive in the absence of a sugar group. Ursolic acid,
330 which exhibited a better inhibitory effect of preadipocyte differentiation, possesses a similar
331 structure as compound **1s** with the beta-hydroxyl at C-3 instead of alfa-hydroxyl.²³ Thus, in
332 addition to glycoside, the numbers and the orientation of the hydroxyl groups play an important
333 role in the inhibitory effect of ursolic acid type triterpenoid on lipid accumulation. In addition,
334 ursane-type triterpenoids exhibited multiple biological functions, such as antioxidant,
335 antimicrobial, antiplatelet aggregation, and reducing serum total cholesterol activities.²⁴⁻²⁷
336 Apigenin (**5s**), an aglycone of compound **5**, showed an enhanced inhibitory effect with an IC₅₀
337 value of 34.6 μ g/mL when compared to compound **5**. This complements the literature in that
338 flavonoids without a sugar group provide stronger anti-adipogenic effects.²⁸ However, this
339 result opposes that of triterpenoid saponin. Therefore, the triterpenoid saponin (**1**) and
340 flavonoid (**5s**) both showed anti-adipogenic potential for obesity prevention.

341 In conclusion, bioactivity-guided isolation of Shiya tea led to the isolation and
342 identification of four triterpenoid saponins (**1–4**), including one new compound, and a
343 flavonoid (**5**) using NMR (1D and 2D NMR) and tandem liquid chromatography mass

344 spectrometry (HPLC-ESI/MS²) techniques. A comprehensive profile of isolates in Shiya tea
345 was outlined by LC-MS. Compound **1** could reduce intracellular lipid accumulation in 3T3-L1
346 adipocytes in a dose-dependent manner with an IC₅₀ value of 27.6 μg/mL. Previous studies
347 indicated that flavonoids in Shiya tea are considered the major active and functional chemical
348 constituents. However, this study found a new triterpenoid, saponin, to be the major anti-
349 adipogenic constituent in Shiya tea. Three hydrolytic compounds (**1s**, **2s**, and **5s**) were obtained
350 and screened for their effect on lipid accumulation inhibition. The inhibitory activity of the
351 triterpenoid (**1s**) without a sugar group decreased significantly, while the flavonoid (**5s**) without
352 a sugar showed great increased activity.

353

354 **ASSOCIATED CONTENT**

355 **Supporting Information**

356 The 1D, 2D NMR, HRESIMS of compound **1**; Table of anti-adipogenic effects of the
357 fractions.

358

359 **AUTHORS INFORMATION**

360 **Corresponding Authors**

361 *Telephone: +1-863-956-8673. E-mail: yu.wang@ufl.edu

362 **Author Contributions**

363 [†]These authors contributed equally to this work.

364 **ORCID**

365 Yu Wang: 0000-0002-2003-270X

366

367 **Notes**

368 The authors declare no competing financial interest.

369

370 **Acknowledgements**

371 We thank Laura Reuss (Citrus Research and Education Center, University of Florida) for
372 editing the manuscript.

373

374 **REFERENCES**

375 (1) Tremmel, M.; Gerdtham, U. G.; Saha, S.; Gerdtham, U. G.; Saha, S.; Gerdtham, U. G.;
376 Nilsson, P. M. Economic burden of obesity: a systematic literature review. *Int J Environ Res*
377 *Public Health* **2017**, *14*, 435.

378 (2) Puhl, R. M.; Heuer, C. A. The stigma of obesity: a review and update. *Obesity* **2009**, *17*,
379 941-964.

380 (3) Sung, J.; Ho, C. T.; Wang, Y. Preventive mechanism of bioactive dietary foods on obesity-
381 related inflammation and diseases. *Food Funct.* **2018**, *9*, 6081-6095.

382 (4) WHO (World Health Organization), Global Health Observatory (GHO) data, 2016,
383 https://www.who.int/gho/ncd/risk_factors/overweight_text/en/.

384 (5) Jeong, G. H.; Cho, J. H.; Kim, S. H.; Kim, T. H. Plasma-induced dimerization of phloridzin
385 as a new class of anti-adipogenic agents. *Bioorg. Med. Chem. Lett.* **2017**, *27*, 4889-4892.

386 (6) Min T. L.; Bruce B. *Flora of China*; Science Press: Beijing, **2007**, *12*, 442.

387 (7) Chen, Y.; Chen, G.; Fu, X.; Liu, R. H. Phytochemical profiles and antioxidant activity of
388 different varieties of *Adinandra tea* (*Adinandra* Jack). *J. Agric. Food Chem.* **2015**, *63*, 169-
389 176.

390 (8) Chen, Y.; Ma, X.; Fu, X.; Yan, R. Phytochemical content, cellular antioxidant activity and
391 antiproliferative activity of *Adinandra nitida* tea (Shiyacha) infusion subjected to in vitro
392 gastrointestinal digestion. *RSC Adv.* **2017**, *7*, 50430-50440.

393 (9) Chen, Y.; Shen, Y.; Fu, X.; Abbasi, A. M.; Yan, R. Stir-frying treatments affect the
394 phenolics profiles and cellular antioxidant activity of *Adinandra nitida* tea (Shiyacha) in daily
395 tea model. *Int. J. Food Sci. Technol.* **2017**, *52*, 1820-1827.

396 (10) Liu, B.; Yang, J.; Ma, Y.; Yuan, E.; Chen, C. Antioxidant and angiotensin converting

- 397 enzyme (ACE) inhibitory activities of ethanol extract and pure flavonoids from *Adinandra*
398 *nitida* leaves. *Pharm. Biol.* **2011**, *48*, 1432-1438.
- 399 (11) Gao, H.; Liu, B.; Liu, F.; Chen, Y. Anti-proliferative effect of camellianin A in *Adinandra*
400 *nitida* leaves and its apoptotic induction in human Hep G2 and MCF-7 cells. *Molecules* **2010**,
401 *15*, 3878-3886.
- 402 (12) Yuan, E.; Liu, B.; Ning, Z. Preparation and antioxidant activity of camellianin A from
403 *Adinandra nitida* leaves. *J. Food Process. Preserv.* **2008**, *32*, 785-797.
- 404 (13) Yuan, E.; Liu, B.; Ning, Z.; Chen, C. Preparative separation of flavonoids in *Adinandra*
405 *nitida* leaves by high-speed counter-current chromatography and their effects on human
406 epidermal carcinoma cancer cells. *Food Chem.* **2009**, *115*, 1158-1163.
- 407 (14) Qin, X. J.; Sun, D. J.; Ni, W.; Chen, C. X.; Hua, Y.; He, L.; Liu, H. Y. Steroidal saponins
408 with antimicrobial activity from stems and leaves of *Paris polyphylla* var. *yunnanensis*.
409 *Steroids* **2012**, *77*, 1242-1248.
- 410 (15) Feng, S.; Niu, L.; Suh, J. H.; Hung, W. L.; Wang, Y. Comprehensive metabolomics
411 analysis of Mandarins (*Citrus reticulata*) as a tool for variety, rootstock, and grove
412 discrimination. *J. Agri. Food Chem.* **2018**, *66*, 10317-10326.
- 413 (16) Sung, J.; Bang, M. H.; Lee, J. Bioassay-guided isolation of anti-adipogenic compounds
414 from defatted pepper (*Capsicum annum* L.) seeds. *J. Func. Foods* **2015**, *14*, 670-675.
- 415 (17) Guang, Y. L.; Gray, A. I.; Waterman, P. G. Pentacyclic triterpenes from the fruits of *Rosa*
416 *sterilis*. *J. Nat. Prod.* **1989**, *52*, 162-166.
- 417 (18) Lontsi, D.; Sondengam, B. L.; Ayafor, J. F.; Tsoupras, M. G.; Tabacchi, R. Further
418 triterpenoids of *Musanga cecropioides*: the structure of cecropic acid. *Planta Med.* **1990**, *56*,
419 287-9.
- 420 (19) Wang, Y.; Ye, W. C.; Yin, Z. Q.; Zhao, S. X. Triterpene saponins from *Adinandra nitida*.
421 *Yao Xue Xue Bao* **2008**, *43*, 504-8.
- 422 (20) Liu, B.; Ma, Y.; Liu, Y.; Yang, Z.; Zhang, L. Ultrasonic-assisted extraction and
423 antioxidant activity of flavonoids from *Adinandra nitida* leaves. *Trop. J. Pharm. Res.* **2013**,
424 *12*, 1045-1051.
- 425 (21) Bhandari, S. P. S.; Garg, H. S.; Agrawal, P. K.; Bhakuni, D. S. Ursane triterpenoids from
426 *Nepeta eriostachia*. *Phytochemistry* **1990**, *29*, 3956-8.
- 427 (22) Gong, S. S.; Liu, Y. L.; Li, Y.; Li, X.R.; Feng, Y. L.; Xu, Q. M.; Yang, S. L. Chemical
428 constituents from whole plant of *Gynura procumbens* (I). *Zhongcaoyao* **2016**, *47*, 1856-1860.
- 429 (23) He, Y.; Li, Y.; Zhao, T.; Wang, Y.; Sun, C. Ursolic acid inhibits adipogenesis in 3T3-L1
430 adipocytes through LKB1/AMPK Pathway. *Plos One* **2013**, *8*, e70135.
- 431 (24) Yang, H. M.; Yin, Z. Q.; Zhao, M. G.; Jiang, C. H.; Zhang, J.; Pan, K. Pentacyclic
432 triterpenoids from *Cyclocarya paliurus* and their antioxidant activities in FFA-induced HepG2
433 steatosis cells. *Phytochemistry* **2018**, *151*, 119-127.
- 434 (25) Bisoli, E.; Garcez, W. S.; Hamerski, L.; Tieppo, C.; Garcez, F. R. Bioactive pentacyclic
435 triterpenes from the stems of *Combretum laxum*. *Molecules* **2008**, *13*, 2717-2728.
- 436 (26) Yang, B.; Zhu, J. P.; Rong, L.; Jin, J.; Cao, D.; Li, H.; Zhou, X. H.; Zhao, Z. X.
437 Triterpenoids with antiplatelet aggregation activity from *Ilex rotunda*. *Phytochemistry* **2018**,
438 *145*, 179-186.
- 439 (27) Liu, C.; Shen, Y. J.; Tu, Q. B.; Zhao, Y. R.; Guo, H.; Wang, J.; Zhang, L.; Shi, H. W.;
440 Sun, Y. Pedunculoside, a novel triterpene saponin extracted from *Ilex rotunda*, ameliorates
441 high-fat diet induced hyperlipidemia in rats. *Biomed. Pharmacother.* **2018**, *101*, 608-616.
- 442 (28) Yang, Z. G.; Wen, X. F.; Li, Y. H.; Matsuzaki, K.; Kitanaka, S. Inhibitory Effects of the
443 Constituents of *Hippophae rhamnoides* on 3T3-L1 cell differentiation and nitric oxide

444 production in RAW264.7 Cells. *Chem. Pharm. Bull.* **2013**, *61*, 279-285.

445 **Table and figure captions**

446 **Table 1.** ^1H and ^{13}C NMR spectroscopic data of compound **1** in CD_3OD .

447 **Table 2.** MS precursor and fragment ions of the isolates (**1–5**) in Shiya tea.

448 **Figure 1.** Effects of the fractions of *A. nitida* on lipid accumulation during 3T3-L1 adipocyte
449 differentiation (quercetin was used as positive control. $**p < 0.01$ vs. control, $*p < 0.05$ vs.
450 control). Data are expressed as a mean \pm standard deviation ($n = 3$). The cells were treated with
451 the extracts of ethyl acetate and water, the fractions of Fr.1–4 at 200 $\mu\text{g}/\text{mL}$, the fractions of
452 Fr.1–4, Fr.3A–3E, and Fr.3B.1–3B.4 at 100 $\mu\text{g}/\text{mL}$, and the fractions of Fr.2 and Fr.3A, and
453 quercetin at 50 $\mu\text{g}/\text{mL}$.

454 **Figure 2.** Chemical structures of **1–5**.

455 **Figure 3.** Key 2D NMR correlations of **1**

456 **Figure 4.** Total ion chromatogram (TIC) of the isolates (**1–5**) in Shiya tea extract.

457 **Figure 5.** Effect of compounds **1–5** on lipid accumulation during 3T3-L1 adipocytes
458 differentiation. (quercetin was used as positive control. $**p < 0.01$ vs. control) Data are
459 expressed as a mean \pm standard deviation ($n = 3$).

460 **Figure 6.** Inhibitory effects of compound **1** and **5s** on intracellular lipid accumulation and
461 lipid droplets during adipocytes differentiation. Quantification of intracellular lipid in Oil red
462 O stained adipocytes (A). Representative images of Oil red O staining after various amounts
463 of compounds were added (B). Data are expressed as a mean \pm standard deviation ($n = 3$).

464 **For Table of Contents Only.**


465 **Table 1.** ^1H and ^{13}C NMR spectroscopic data of compound **1** in CD_3OD .

No.	δ_{H} (J in Hz)	δ_{C} , type
1	α : 1.28, m β : 1.63, m	41.3, CH_2
2	3.94, dt (11.8, 3.5)	65.8, CH
3	3.34, d (3.5)	78.7, CH
4		38.1, C
5	1.25, m	47.9, CH
6	α : 1.46, m β : 1.39, m	17.7, CH_2
7	α : 1.58, m β : 1.35, m	32.8, CH_2
8		39.8, C
9	1.72, t (8.4)	47.2, CH
10		37.9, C
11	α : 1.98, m β : 1.99, m	23.0, CH_2
12	5.28, t (2.9)	125.7, CH
13		137.8, C
14		42.0, C
15	α : 1.11, m β : 1.96, m	27.9, CH_2
16	α : 1.78, m β : 2.10, td (12.5, 4.0)	23.8, CH_2
17		48.1, C
18	2.26, d (11.0)	52.8, CH
19	1.42, m	39.1, CH
20	1.02, m	38.9, CH
21	α : 1.53, m β : 1.37, m	30.3, CH_2
22	α : 1.65, m β : 1.78, m	36.1, CH_2
23	1.00, s	27.9, CH_3
24	0.88, s	21.1, CH_3
25	1.03, s	15.7, CH_3
26	0.85, s	16.5, CH_3
27	1.15, s	22.7, CH_3
28		176.6, C
29	0.92, d (6.2)	16.2, CH_3
30	0.99, d (5.2)	20.1, CH_3
1'	5.36, d (8.6)	93.4, CH
2'	3.34, m	72.5, CH
3'	3.35, m	77.2, CH
4'	3.38, m	69.8, CH
5'	3.42, m	76.9, CH

466	6'	a:3.70, dd (11.8, 4.2) b:3.82, dd (11.8, 2.0)	61.1, CH ₂
-----	----	--	-----------------------



467 **Table 2.** MS precursor and fragment ions of the isolate (**1–5**) in Shiya tea.

Com.	$[M - H]^-$	$[M + \text{HCOOH} - \text{H}]^-$	MS^2
1	633.3985	679.4064	633.3985/471.3471 $[M - \text{Glu} - \text{H}]^-$
2	649.3881	695.4014	649.3881/487.3424 $[M - \text{Glu} - \text{H}]^-$, 425.3475 $[M - \text{Glu} - \text{CO}_2 - \text{H}_2\text{O} - \text{H}]^-$, 407.3346 $[M - \text{Glu} - \text{CO}_2 - 2\text{H}_2\text{O} - \text{H}]^-$
3	649.3881	695.4014	649.3881/487.3426 $[M - \text{Glu} - \text{H}]^-$, 469.3304 $[M - \text{Glu} - \text{H}_2\text{O} - \text{H}]^-$
4	649.4072	695.4019	649.4072/487.3427 $[M - \text{Glu} - \text{H}]^-$, 469.3325 $[M - \text{Glu} - \text{H}_2\text{O} - \text{H}]^-$
5	619.1654	Not detected	619.1654/601.1686 $[M - \text{H}_2\text{O} - \text{H}]^-$, 577.1569 $[M - \text{C}_6\text{H}_5\text{CO} - \text{H}]^-$, 269.0456 $[M - \text{Glu} - \text{CH}_3\text{CO} - \text{Rha} - \text{H}]^-$



469

470 **Figure 1.**




5 R = -Rham-Glc-OCCH₃

5s R = H

	R ₁	R ₂	R ₃	R ₄	R ₅	R ₆
1	α-OH	CH ₃	H	H	CH ₃	β-D-Glucopyranosyl
1s	α-OH	CH ₃	H	H	CH ₃	H
2	α-OH	CH ₃	OH	H	CH ₃	β-D-Glucopyranosyl
2s	α-OH	CH ₃	OH	H	CH ₃	H
3	β-OH	CH ₃	OH	H	CH ₃	β-D-Glucopyranosyl
4	α-OH	H	OH	CH ₃	CH ₃	β-D-Glucopyranosyl

471


472 **Figure 2.**



473


474 **Figure 3.**

475



476

477 **Figure 4.**




478

479

Figure 5.

480

481




482

483

Figure 6.

484



485

486

487 **For Table of Contents Only.**